ISPC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
iSpecimen Inc (ISPC) is not a good buy for a beginner investor with a long-term strategy at this time. Despite a recent surge in post-market trading and a positive news catalyst, the company's financial performance is extremely weak, and technical indicators do not suggest a strong upward trend. The lack of significant hedge fund or insider activity, poor financials, and no proprietary trading signals make this stock a high-risk investment for a long-term beginner investor.
The MACD is slightly positive and expanding, but the RSI is neutral at 31.128, indicating no clear trend. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key resistance levels (R1: 0.182, R2: 0.206). The stock's recent price action shows volatility, but there is no strong technical signal for a long-term buy.
The company announced a new logistics model that significantly reduces biospecimen shipping times, which could enhance customer satisfaction and reduce costs. This news caused a 91% stock surge in the short term.
The company's financials are extremely weak, with revenue dropping by -96.49% YoY, net income down -17.29% YoY, and gross margin plummeting to -1039.51%. Additionally, there is no significant hedge fund or insider activity, and the stock has no recent proprietary trading signals.
In Q4 2025, the company's revenue dropped significantly to $51,761 (-96.49% YoY), net income fell to -$5,001,245 (-17.29% YoY), and EPS declined to -0.65 (-87.83% YoY). The gross margin also turned deeply negative at -1039.51%, indicating severe financial challenges.
No analyst rating or price target changes available for ISPC.
